Search research articles
Contact Us
Filters
Showing results (81-90 of 87) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
October 26, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
Zeitschrift Fur Gastroenterologie
|
December 17, 2013
[S3-guideline exocrine pancreatic cancer]
T Seufferlein, M Porzner, T Becker, et al.
Zeitschrift Fur Gastroenterologie
|
April 9, 2011
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]
M Moehler, S-E Al-Batran, T Andus, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 87) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
October 26, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
Zeitschrift Fur Gastroenterologie
|
December 17, 2013
[S3-guideline exocrine pancreatic cancer]
T Seufferlein, M Porzner, T Becker, et al.
Zeitschrift Fur Gastroenterologie
|
April 9, 2011
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]
M Moehler, S-E Al-Batran, T Andus, et al.
Page
of 9